RxDoctor Payments Data

Raymon Hanna, DPM

Foot & Ankle Surgery · Palm Harbor, FLNPI 1518371616

Payments from drug & device makers

What this record shows

This record is dominated by other: $43,983 of the $50,747 with a category attached, or 86.7%. Smith+Nephew accounts for 87.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $34,898 and has fallen 98.0% since, to $689 in 2025. Among foot & ankle surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,747in general payments, 2019–2025

Across 101 payments — averaging $502.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$44K
  • Arthrex$3K
  • Orthofix Medical, Inc.$1K
  • Paragon 28, Inc.$1K
  • Integra Lifesciences Corporation$402
  • Stryker$390
  • plus $724 from 17 others

What the payments were for

  • Travel & lodging$2,2304%
  • Food & beverage$1,9534%
  • Education$2,5805%
  • Other$43,98387%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,747 in reported general payments places this provider in the 90th percentile of 850 foot & ankle surgery providers in Florida.

See all foot & ankle surgery providers in Florida

Medicare billing

Part B allowed, 2024
$91,526
Medicare patients
162
Services billed
785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.16$5,469
Ciclopirox18$451
Doxycycline Hyclate54$311
Ciprofloxacin Hcl14$100
Cephalexin25$90
Silver Sulfadiazine14$89
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$79
Methylprednisolone11$57
Meloxicam13$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$44,286$5,46916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 850 foot & ankle surgery providers in Florida.

Other foot & ankle surgery in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →